http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Aug 2026 07:09:29 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Gossamer+Bio+Inc.+%28GOSS%29/26984626.html <p>H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $2.00 price target on Gossamer Bio Inc. (NASDAQ: GOSS).</p><p>The analyst commented: "Following receipt of the official pre-NDA Type B meeting minutes announced on July 27, Gossamer remains on track to submit an NDA for seralutinib in pulmonary arterial hypertension (PAH) in September, supported by one adequate and well-controlled trial, the Phase 3 trial (PROSERA), plus confirmatory evidence from the Phase 2 trial (TORREY) and supportive analyses. Critically, the minutes characterize the degree of statistical significance and the magnitude of the PROSERA treatment effect as review issues rather than filing issues, http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Gossamer+Bio+Inc.+%28GOSS%29/26984626.html Thu, 27 Aug 2026 07:09:29 -0400 GOSS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Christian+Waage/26983094.html si-local-file:///var/storage/secattach/20260826/26983094.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Christian+Waage/26983094.html Wed, 26 Aug 2026 18:13:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Christian+Waage/26983094.html si-local-file:///var/storage/secattach/20260826/26983094.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Christian+Waage/26983094.html Wed, 26 Aug 2026 18:13:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Peterson+Caryn/26983091.html si-local-file:///var/storage/secattach/20260826/26983091.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Peterson+Caryn/26983091.html Wed, 26 Aug 2026 18:12:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Peterson+Caryn/26983091.html si-local-file:///var/storage/secattach/20260826/26983091.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Peterson+Caryn/26983091.html Wed, 26 Aug 2026 18:12:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Smith+Robert+Paul+JR/26983089.html si-local-file:///var/storage/secattach/20260826/26983089.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Smith+Robert+Paul+JR/26983089.html Wed, 26 Aug 2026 18:11:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Smith+Robert+Paul+JR/26983089.html si-local-file:///var/storage/secattach/20260826/26983089.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Smith+Robert+Paul+JR/26983089.html Wed, 26 Aug 2026 18:11:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Giraudo+Bryan/26983087.html si-local-file:///var/storage/secattach/20260826/26983087.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Giraudo+Bryan/26983087.html Wed, 26 Aug 2026 18:10:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Giraudo+Bryan/26983087.html si-local-file:///var/storage/secattach/20260826/26983087.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Giraudo+Bryan/26983087.html Wed, 26 Aug 2026 18:10:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Hasnain+Faheem/26983084.html si-local-file:///var/storage/secattach/20260826/26983084.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Hasnain+Faheem/26983084.html Wed, 26 Aug 2026 18:08:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Hasnain+Faheem/26983084.html si-local-file:///var/storage/secattach/20260826/26983084.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24++Filed+by%3A+Hasnain+Faheem/26983084.html Wed, 26 Aug 2026 18:08:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24/26981422.html si-local-file:///var/storage/secattach/20260826/26981422.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24/26981422.html Wed, 26 Aug 2026 16:02:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24/26981422.html si-local-file:///var/storage/secattach/20260826/26981422.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+24/26981422.html Wed, 26 Aug 2026 16:02:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+D.+E.+SHAW+%26amp%3B+CO%2C+L.P./26969548.html si-local-file:///var/storage/secattach/20260824/26969548.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+D.+E.+SHAW+%26amp%3B+CO%2C+L.P./26969548.html Mon, 24 Aug 2026 20:12:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+D.+E.+SHAW+%26amp%3B+CO%2C+L.P./26969548.html si-local-file:///var/storage/secattach/20260824/26969548.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Gossamer+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+D.+E.+SHAW+%26amp%3B+CO%2C+L.P./26969548.html Mon, 24 Aug 2026 20:12:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+20/26958594.html si-local-file:///var/storage/secattach/20260821/26958594.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+20/26958594.html Fri, 21 Aug 2026 08:01:00 -0400 GOSS O.38966322 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+20/26958594.html si-local-file:///var/storage/secattach/20260821/26958594.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Gossamer+Bio%2C+Inc.++++++++For%3A+Aug+20/26958594.html Fri, 21 Aug 2026 08:01:00 -0400 GOSS O.38966322 http://www.streetinsider.com/Equity+Offerings/Gossamer+Bio+raises+up+to+%24250M+in+private+placement+for+PAH+drug/26958574.html <p>Gossamer Bio, Inc. (Nasdaq: GOSS) has entered into a securities purchase agreement for a private placement expected to generate up to approximately $250 million in gross proceeds, before placement agent fees and offering expenses, according to a company press release.</p> <p>The financing consists of three components. An initial closing, expected around August 24, 2026, will provide approximately $25 million through the sale of pre-funded warrants at $0.1399 per warrant. A second closing, contingent on FDA acceptance of the company's seralutinib new drug application (NDA) for pulmonary arterial hypertension (PAH) occurring in 2026, would provide an additional approximately $125 million. Together, these http://www.streetinsider.com/Equity+Offerings/Gossamer+Bio+raises+up+to+%24250M+in+private+placement+for+PAH+drug/26958574.html Fri, 21 Aug 2026 08:00:18 -0400 A.36817542 GOSS O.25213119 O.38966322 http://www.streetinsider.com/Equity+Offerings/Gossamer+Bio+raises+up+to+%24250M+in+private+placement+for+PAH+drug/26958574.html <p>Gossamer Bio, Inc. (Nasdaq: GOSS) has entered into a securities purchase agreement for a private placement expected to generate up to approximately $250 million in gross proceeds, before placement agent fees and offering expenses, according to a company press release.</p> <p>The financing consists of three components. An initial closing, expected around August 24, 2026, will provide approximately $25 million through the sale of pre-funded warrants at $0.1399 per warrant. A second closing, contingent on FDA acceptance of the company's seralutinib new drug application (NDA) for pulmonary arterial hypertension (PAH) occurring in 2026, would provide an additional approximately $125 million. Together, these http://www.streetinsider.com/Equity+Offerings/Gossamer+Bio+raises+up+to+%24250M+in+private+placement+for+PAH+drug/26958574.html Fri, 21 Aug 2026 08:00:18 -0400 A.36817542 GOSS O.25213119 O.38966322 http://www.streetinsider.com/Equity+Offerings/Gossamer+Bio+raises+up+to+%24250M+in+private+placement+for+PAH+drug/26958574.html <p>Gossamer Bio, Inc. (Nasdaq: GOSS) has entered into a securities purchase agreement for a private placement expected to generate up to approximately $250 million in gross proceeds, before placement agent fees and offering expenses, according to a company press release.</p> <p>The financing consists of three components. An initial closing, expected around August 24, 2026, will provide approximately $25 million through the sale of pre-funded warrants at $0.1399 per warrant. A second closing, contingent on FDA acceptance of the company's seralutinib new drug application (NDA) for pulmonary arterial hypertension (PAH) occurring in 2026, would provide an additional approximately $125 million. Together, these http://www.streetinsider.com/Equity+Offerings/Gossamer+Bio+raises+up+to+%24250M+in+private+placement+for+PAH+drug/26958574.html Fri, 21 Aug 2026 08:00:18 -0400 A.36817542 GOSS O.25213119 O.38966322 http://www.streetinsider.com/Equity+Offerings/Gossamer+Bio+raises+up+to+%24250M+in+private+placement+for+PAH+drug/26958574.html <p>Gossamer Bio, Inc. (Nasdaq: GOSS) has entered into a securities purchase agreement for a private placement expected to generate up to approximately $250 million in gross proceeds, before placement agent fees and offering expenses, according to a company press release.</p> <p>The financing consists of three components. An initial closing, expected around August 24, 2026, will provide approximately $25 million through the sale of pre-funded warrants at $0.1399 per warrant. A second closing, contingent on FDA acceptance of the company's seralutinib new drug application (NDA) for pulmonary arterial hypertension (PAH) occurring in 2026, would provide an additional approximately $125 million. Together, these http://www.streetinsider.com/Equity+Offerings/Gossamer+Bio+raises+up+to+%24250M+in+private+placement+for+PAH+drug/26958574.html Fri, 21 Aug 2026 08:00:18 -0400 A.36817542 GOSS O.25213119 O.38966322 http://www.streetinsider.com/FDA/Gossamer+Bio+raises+up+to+%24250M+in+private+placement+for+PAH+drug/26958574.html <p>Gossamer Bio, Inc. (Nasdaq: GOSS) has entered into a securities purchase agreement for a private placement expected to generate up to approximately $250 million in gross proceeds, before placement agent fees and offering expenses, according to a company press release.</p> <p>The financing consists of three components. An initial closing, expected around August 24, 2026, will provide approximately $25 million through the sale of pre-funded warrants at $0.1399 per warrant. A second closing, contingent on FDA acceptance of the company's seralutinib new drug application (NDA) for pulmonary arterial hypertension (PAH) occurring in 2026, would provide an additional approximately $125 million. Together, these http://www.streetinsider.com/FDA/Gossamer+Bio+raises+up+to+%24250M+in+private+placement+for+PAH+drug/26958574.html Fri, 21 Aug 2026 08:00:18 -0400 A.36817542 GOSS O.25213119 O.38966322 http://www.streetinsider.com/FDA/Gossamer+Bio+raises+up+to+%24250M+in+private+placement+for+PAH+drug/26958574.html <p>Gossamer Bio, Inc. (Nasdaq: GOSS) has entered into a securities purchase agreement for a private placement expected to generate up to approximately $250 million in gross proceeds, before placement agent fees and offering expenses, according to a company press release.</p> <p>The financing consists of three components. An initial closing, expected around August 24, 2026, will provide approximately $25 million through the sale of pre-funded warrants at $0.1399 per warrant. A second closing, contingent on FDA acceptance of the company's seralutinib new drug application (NDA) for pulmonary arterial hypertension (PAH) occurring in 2026, would provide an additional approximately $125 million. Together, these http://www.streetinsider.com/FDA/Gossamer+Bio+raises+up+to+%24250M+in+private+placement+for+PAH+drug/26958574.html Fri, 21 Aug 2026 08:00:18 -0400 A.36817542 GOSS O.25213119 O.38966322 http://www.streetinsider.com/FDA/Gossamer+Bio+raises+up+to+%24250M+in+private+placement+for+PAH+drug/26958574.html <p>Gossamer Bio, Inc. (Nasdaq: GOSS) has entered into a securities purchase agreement for a private placement expected to generate up to approximately $250 million in gross proceeds, before placement agent fees and offering expenses, according to a company press release.</p> <p>The financing consists of three components. An initial closing, expected around August 24, 2026, will provide approximately $25 million through the sale of pre-funded warrants at $0.1399 per warrant. A second closing, contingent on FDA acceptance of the company's seralutinib new drug application (NDA) for pulmonary arterial hypertension (PAH) occurring in 2026, would provide an additional approximately $125 million. Together, these http://www.streetinsider.com/FDA/Gossamer+Bio+raises+up+to+%24250M+in+private+placement+for+PAH+drug/26958574.html Fri, 21 Aug 2026 08:00:18 -0400 A.36817542 GOSS O.25213119 O.38966322 http://www.streetinsider.com/FDA/Gossamer+Bio+raises+up+to+%24250M+in+private+placement+for+PAH+drug/26958574.html <p>Gossamer Bio, Inc. (Nasdaq: GOSS) has entered into a securities purchase agreement for a private placement expected to generate up to approximately $250 million in gross proceeds, before placement agent fees and offering expenses, according to a company press release.</p> <p>The financing consists of three components. An initial closing, expected around August 24, 2026, will provide approximately $25 million through the sale of pre-funded warrants at $0.1399 per warrant. A second closing, contingent on FDA acceptance of the company's seralutinib new drug application (NDA) for pulmonary arterial hypertension (PAH) occurring in 2026, would provide an additional approximately $125 million. Together, these http://www.streetinsider.com/FDA/Gossamer+Bio+raises+up+to+%24250M+in+private+placement+for+PAH+drug/26958574.html Fri, 21 Aug 2026 08:00:18 -0400 A.36817542 GOSS O.25213119 O.38966322